A variety of treatment modalities exist for individuals with type 2 diabetes ellitus (T2D). In addition to dietary and physical activity interventions, T2D is also treated pharmacologically with nine major classes of approved drugs. These medications nclude insulin and its analogues, sulfonylureas, biguanides, thiazolidinediones (TZDs), eglitinides, α-glucosidase inhibitors, amylin analogues, incretin hormone mimetics, and ipeptidyl peptidase 4 (DPP4) inhibitors. Pharmacological treatment strategies for T2D are typically based on efficacy, yet favorable responses to such therapeutics are oftentimes ariable and difficult to predict. Characterization of drug response is expected to ubstantially enhance our ability to provide patients with the most effective treatment strategy given their individual backgrounds, yet pharmacogenetic study of diabetes medications is still in its infancy. To date, major pharmacogenetic studies have focused on response to sulfonylureas, biguanides, and TZDs. Here, we provide a comprehensive review of pharmacogenetics investigations of these specific anti-diabetes medications. We focus not only on the results of these studies, but also on how experimental design, study ample issues, and definition of 'response' can significantly impact our interpretation of findings. Understanding the pharmacogenetics of anti-diabetes medications will provide critical baseline information for the development and implementation of genetic screening into therapeutic decision making, and lay the foundation for "individualized medicine" for patients with T2D.
DiStefano, J. K., & Watanabe, R. M. (2010). Pharmacogenetics of Anti-diabetes drugs. Pharmaceuticals. https://doi.org/10.3390/ph3082610